Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Mallinckrodt
Cerilliant
Farmers Insurance
Johnson and Johnson
Covington
Argus Health
Harvard Business School
US Department of Justice
Medtronic

Generated: August 21, 2017

DrugPatentWatch Database Preview

ZEMPLAR Drug Profile

« Back to Dashboard

What is the patent landscape for Zemplar, and what generic Zemplar alternatives are available?

Zemplar is a drug marketed by Abbvie and is included in two NDAs. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has fifteen patent family members in ten countries.

The generic ingredient in ZEMPLAR is paricalcitol. There are ten drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the paricalcitol profile page.

Summary for Tradename: ZEMPLAR

Patents:2
Applicants:1
NDAs:2
Suppliers / Packagers: see list3
Bulk Api Vendors: see list39
Clinical Trials: see list32
Patent Applications: see list732
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZEMPLAR at DailyMed

Pharmacology for Tradename: ZEMPLAR

Ingredient-typeCholecalciferol
Drug ClassVitamin D3 Analog
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606-001May 26, 2005ABRXNoNo► Subscribe► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606-003May 26, 2005DISCNNoNo► Subscribe► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606-002May 26, 2005ABRXNoNo► Subscribe► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
SOLUTION;INTRAVENOUS020819-001Apr 17, 1998APRXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606-003May 26, 2005DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZEMPLAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606-002May 26, 2005► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606-001May 26, 2005► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606-002May 26, 2005► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606-003May 26, 2005► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
SOLUTION;INTRAVENOUS020819-002Feb 1, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ZEMPLAR

Drugname Dosage Strength RLD Submissiondate
paricalcitolInjection0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vialsZemplar11/28/2008
paricalcitolCapsules1 mcg and 2 mcgZemplar10/14/2008
paricalcitolCapsules4 mcgZemplar8/25/2008

International Patent Family for Tradename: ZEMPLAR

Country Document Number Estimated Expiration
Denmark1073467► Subscribe
World Intellectual Property Organization (WIPO)9951271► Subscribe
Japan5548079► Subscribe
Japan2011037860► Subscribe
Australia758989► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ZEMPLAR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB04/003United Kingdom► SubscribePRODUCT NAME: PARICALCITOL; REGISTERED: ES SPAIN 64.974 20020809; UK PL 00037/0403 20030721
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
AstraZeneca
Moodys
US Department of Justice
Federal Trade Commission
Argus Health
Colorcon
Deloitte
Chubb
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot